N	Concordance
1	ery 12 hours   for 4 doses on days 1-2, cyclophosphamide IV over 30 minutes on d
2	 ministered after 4 courses of adjuvant cyclophosphamide/doxorubicin/fluorouraci
3	IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bear
4	e, most received 5-FU, doxorubicin, and cyclophosphamide (FAC) as first-line che
5	unosuppressive. Cytotoxic drugs such as cyclophosphamide and azathioprine suppre
6	 ve vincristine via IV push followed by cyclophosphamide IV on day 1 over 30-45 
7	icity of adjuvant chemotherapy with CAF (cyclophosphamide, doxorubicin, fluorour
8	e third of patients may respond to CHOP (cyclophosphamide, doxorubicin, vincrist
9	rgery received either one course of CMF (cyclophosphamide, methotrexate, fluoro
10	 ood stem cell support vs. conventional cyclophosphamide/methotrexate/fluorourac
11	n of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincr
12	udy the curative potential of high dose cyclophosphamide and total body  irradia
13	onal antibody OKT3  given with low-dose cyclophosphamide in patients with advanc
14	days -8 to -5, followed by  intravenous cyclophosphamide on days -4 and -3 and p
15	imens and at least as effective as oral cyclophosphamide for severe lupus nephri
16	reated with total-body irradiation plus cyclophosphamide with or without etopos
17	erience with low dose intravenous pulse cyclophosphamide in the treatment of pat
18	rotection is reversed by treatment with cyclophosphamide (Cy). The present study